Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Swings

Event driven snapshot of Sarepta Therapeutics

Sarepta Therapeutics (SRPT) is back on investor radar after recent share price swings, including a 13% gain over the past week and a 19% move over the past month, against a weaker one year return.

See our latest analysis for Sarepta Therapeutics.

The recent 19.2% 30 day share price return contrasts with a weaker 1 year total shareholder return of a 68.7% decline, suggesting that short term momentum has improved while longer term holders remain under pressure.

If Sarepta’s swings have you thinking about other healthcare names using AI, this could be a good moment to scan 33 healthcare AI stocks

With Sarepta trading at US$19.97 and an intrinsic value estimate suggesting a wide discount, yet sitting only about 8% below the average analyst target, is there still a potential entry point here, or is the market already pricing in future growth?

Most Popular Narrative: 3.1% Undervalued

At a last close of $19.97, the most followed narrative pegs Sarepta’s fair value at about $20.61, leaving a small implied discount that leans heavily on Elevidys and the broader genetic medicines pipeline.

The analysts have a consensus price target of $20.61 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.

Read the complete narrative.

Curious what kind of revenue reset, margin swing, and future profit multiple would need to line up for that fair value to make sense over time.

Result: Fair Value of $20.61 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story can change quickly if ELEVIDYS safety concerns deepen or if high research and collaboration costs continue to pressure margins and delay any path to profitability.

Find out about the key risks to this Sarepta Therapeutics narrative.

Another View: Market Ratio Signals

The earlier fair value work suggests Sarepta is trading at a wide discount, yet the market is not treating it as an obvious bargain on every metric. On a P/S of about 1x versus a fair ratio of 0.8x, the shares screen as expensive on this yardstick, even though the wider biotech group averages a much higher 10.2x and peers average 13.1x. That mix of apparent value and premium raises a simple question for you: is the discount a genuine opportunity or just the market pricing in the business risks ahead?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of pressure and potential feels split, consider it a reminder to check the numbers yourself, weigh both sides, and review the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Sarepta has sparked your curiosity, do not stop here. Use the Simply Wall St Screener to compare fresh opportunities and sharpen your watchlist before the next move.

• Target potential mispricing by scanning 62 high quality undervalued stocks that pair solid fundamentals with a price tag that might not fully reflect their underlying business strength.
• Prioritize stability and sleep better at night by reviewing 64 resilient stocks with low risk scores that score well on balance sheet strength and volatility metrics.
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before they attract wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com